Comparing S.T.O.P.® contact lenses to MiSight® lenses for slowing myopia in children

Contact Lenses Utilising S.T.O.P.® Technology Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children: A Three-year Prospective, Multi-centre, Controlled, Masked, Randomised, Non Inferiority Clinical Trial

This study is testing if S.T.O.P.® contact lenses can slow down worsening eyesight in children aged 8 to 14 better than MiSight® lenses.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 441 (estimated)
• Ages: 8 Years to 14 Years
• Sex: All
• Sponsor: nthalmic Pty Ltd (Research network)
• Locations: 8 sites (Wenzhou, Lucheng District and 7 other locations)
• Trial ID: NCT05243836 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness of S.T.O.P.® technology contact lenses in comparison to MiSight® contact lenses in slowing the progression of myopia in children aged 8 to 14. Participants will be randomly assigned to wear one of three types of contact lenses daily for a duration of approximately 36 months, with follow-up visits scheduled every six months. The study involves standard, non-invasive clinical tests to monitor myopia progression throughout the trial period.

Who should consider this trial

Good fit: Ideal candidates for this study are children aged 8 to 14 who are experiencing myopia.

Not a fit: Patients who do not have myopia or are outside the age range of 8 to 14 may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective option for managing myopia progression in children.

How similar studies have performed: Other studies have shown success with similar approaches in managing myopia progression, indicating a promising avenue for treatment.

Eligibility criteria

Inclusion Criteria:

* Be between 8-14.
* Have:

  * Read the Informed Assent.
  * Been explained the Informed Assent.
  * Indicated an understanding of the Informed Assent.
  * Signed the Informed Assent.
* Have their parent / legal guardian:

  * Read the Informed Consent.
  * Been explained the Informed Consent.
  * Indicated an understanding of the Informed Consent.
  * Signed the Informed Consent.
* Along with their parent / legal guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to study requirements.
* Along with their parent / legal guardian, agree to maintain the visit schedule .
* Agree to wear allocated contact lenses for a minimum of 5 days per week, at least 6 hours per day on days lenses are worn but not \> 16 hours per day, and to remove lenses at night (i.e., daily wear only with no contact lens wear during sleep), for their duration of the study and to inform the investigator if their schedule is interrupted. Wearing time can be modified by the investigator for health reasons.
* Possess wearable and visually functioning spectacles.
* Be in good general health, based on the parent's / legal guardian's knowledge.
* Have best-corrected high contrast visual acuity based on manifest refraction of 0.10 logMAR (20/25, 6/7.6) or better in each eye.
* Meet the following criteria determined by cycloplegic autorefraction:

  * Spherical equivalent between -0.75 to -4.00 D inclusive.
  * Astigmatism ≥ -1.00 D.

    \*participants who fail astigmatism criterion with autorefraction pass astigmatism criterion if ≥ -0.75 D is measured with subjective refraction.
  * anisometropia ≤ 1.00 D.

Exclusion Criteria:

* Participant is currently, or within 30 days prior to this study, has been an active participant in another study.
* Current or prior use of ANY form of myopia control, including but not limited to:

  * Optical devices.

    * Bifocal / multifocal spectacles of any type.
    * Bifocal / multifocal contact lenses of any type.
    * Orthokeratology of any type.
  * Pharmacological agents.

    * European and Indian sites: Atropine.
    * Chinese sites: Atropine with a concentration \> 0.01%. Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study.
    * Pirenzepine.
* Participant born earlier than 30 weeks or weighed \< 1500 g at birth.
* Habitual use of a systemic or topical medication that may alter normal ocular findings / is known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and / or during the clinical trial.
* A known allergy to sodium fluorescein, benoxinate, proparacaine, or tropicamide.
* Chinese sites: A known allergy to cyclopentolate.
* A known corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections, or any other recurrent ocular infections.
* Strabismus by cover test at distance (3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions.
* Known ocular or systemic disease, such as but not limited to:

  * Diabetes.
  * Graves' disease.
  * Glaucoma.
  * Uveitis.
  * Scleritis.
  * Auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus.
* Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to:

  * Persistent pupillary membrane.
  * Vitreous haemorrhage.
  * Cataract.
  * Central corneal scarring.
  * Eyelid haemangiomas.
  * Marfan's syndrome.
  * Down's syndrome.
  * Ehler's-Danlos syndrome.
  * Stickler's syndrome.
  * Ocular albinism.
  * Retinopathy of prematurity.
* Keratoconus or irregular cornea.
* Biomicroscopic that contraindicate contact lens, such as but limited to:

  * Neovascularisation or ghost vessels ≥ 1.5 mm in from limbus.
  * Any active anterior segment disease that contraindicates safe contact lens wear.
  * Clinically significant giant papillary conjunctivitis.
  * Clinically significant abnormalities of the anterior segment, lids, conjunctiva, sclera, or associated structures.
  * Allergic or seasonal conjunctivitis if the investigator believes it could significantly interfere with maintaining a specified wearing schedule.
* The investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests.

Where this trial is running

Wenzhou, Lucheng District and 7 other locations

• Wenzhou Medical University Eye Hospital — Wenzhou, Lucheng District, China (Active_not_recruiting)
• Tianjin Medical University — Tianjin, Wuqing District, China (Active_not_recruiting)
• Shanghai Fudan University Eye and ENT Hospital — Shanghai, Xuhui District, China (Active_not_recruiting)
• LV Prasad Eye Institute — Hyderabad, Telangana, India (Active_not_recruiting)
• The University of Hyderabad — Hyderabad, Telangana, India (Not_yet_recruiting)
• Centre Universitari de la Visió — Terrassa, Barcelona, Spain (Recruiting)
• Lab. de Superficie Ocular y Lentes de Contacto (SOYLC) — Santiago De Compostela, Galicia, Spain (Recruiting)
• Ocupharm Research Group (Clinica Universitaria de Optometría), Universidad Complutense Madrid — Madrid, Spain (Active_not_recruiting)

Study contacts

• Principal investigator: Daniel Tilia, MOptom, PhD — nthalmic Pty Ltd
• Study coordinator: Daniel Tilia, MOptom, PhD

Conditions Myopia